Stockwatch: Humans – the weak link in drug development
This article was originally published in Scrip
The announcement on 4 September that Gilead Sciences, after consultation with the FDA, will be dropping its experimental anti-hepatitis C virus (HCV) compound GS 9190 (tegobuvir) from ongoing clinical trials after two serious adverse events, will cast doubts on this potentially hot target in the treatment of HCV infections (scripintelligence.com, 5 September 2011).
You may also be interested in...
Can the development of coronavirus vaccines and therapeutics reverse the demonization of the pharmaceutical sector brought about by drug price increases?
A complete response letter from the FDA in June knocked Intercept’s stock price down to 2014 levels, but perhaps the regulator is sending wider messages about NASH.
A complete response letter from the FDA knocked Intercept’s stock price for six, but perhaps the FDA is sending wider messages about NASH.